AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Completed · Phase 2

Conditions studied: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome

In brief

The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.

Key facts

Study ID

NCT00071006

Run by

Pfizer

People needed

12

Starts

2003-09-01

Expected to finish

2004-07-01

Last updated by the study team

2012-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Poor prognosis AML or MDS
• Histological confirmation of diagnosis
• White blood cell count less than or equal to 30,000/mm3
• Adequate hepatic and renal function documented within 14 days prior to registration
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• No evidence of preexisting uncontrolled hypertension
• Not a suitable candidate for chemotherapy
• No prior systemic chemotherapy treatment for AML or MDS or treatment with an anti-angiogenesis agent

You may not qualify if…

• Patients must not have exclusion criteria.
• Candidate for chemotherapy
• Patients with AML M3 (acute promyelocytic leukemia)
• Conditions that might confound the evaluation of safety or efficacy or increase patient risk.

Where it is running

• Pfizer Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.